Cost Effectiveness
Last updated: November 2024
Share this article: - - -
Studies have shown that FeNO-guided asthma management decreased expenditure by up to $624 per patient annually compared to standard care.3,4
In the USA, asthma leads to around 986,453 emergency department visits per year and has previously costed $89.1 billion, including environmental, productivity, and quality of life costs.5,6 Poor asthma control is also linked to higher expenses, accounting for up to 75% of all asthma-related costs.7
As poor asthma control accounts for such a large percentage of asthma costs, getting patients asthma under control could help to bring this down.7,8 Regular in-person asthma assessments, including after an exacerbation, are important to monitor your patient’s asthma, keeping it under control and reducing further risk of exacerbation and hospitalisation.9,10
One test you can implement into this assessment to help understand your patients’ asthma control is FeNO testing. FeNO stands for fractional exhaled nitric oxide and offers a way to directly measure the level of Type 2 airway inflammation in a patient’s lungs, associated with the most common type of asthma.2,11,12
It is quick to perform, with an actionable measurement given instantly at the point-of-care.11 It can help you to visualise if your patient’s asthma is under control; if they are adherent to medication, on the correct medication, have correct inhaler technique, and predict future exacerbations.12-15
FeNO has been shown to be cost effective by identifying non-adherence in patients with difficult-to-control asthma.8,16 FeNO testing can help reduce the risk of exacerbations by up to 50%, resulting in fewer hospital admissions and costs associated.17,18
Discover our latest FeNO webinar today.
FeNO is highly sensitive to inhaled corticosteroids, and studies have shown that it can help to titrate dosage, ensuring your patients are on the best-fit medication for them.14,19 FeNO can also optimise the use of biological therapies, identifying responders for a “right first time” approach, saving costs of therapies unlikely to work.8
Studies have consistently shown that FeNO leads to cost savings when implemented into asthma care.3,8,20-22
Studies have shown that FeNO-guided asthma management decreased expenditure by up to $624 per patient annually compared to standard care ($2,228 vs $2,637 and $2,013 vs. $2637) and increased QALY.3,4
By taking these estimated cost savings and multiplying them by the number of Americans diagnosed with asthma (24.9 million), FeNO testing for asthma management could lead to estimated savings of up to $10 - $15 billion.3,4,5
Learn more about FeNO testing with these recomendations:
Overall, implementing FeNO and a wider use of this simple and non-invasive asthma test could help to significantly reduce costs associated with asthma.21-23 It is important that patients’ asthma remains under control, to allow them to live their lives as symptom-free as possible. The secondary benefit of this is the potential for reduced asthma-associated costs and relieved strain on healthcare resources.17,21-24
FeNO testing is reimbursed throughout the United States with approximately 84% of all insured lives covered.25 This rises to as high as 98% in Indiana, 97% in California, and 89% in Texas.26
Check out our handy Reimbursement calculator to see what reimbursement looks like in your state, or request a demo of the gold standard NIOX VERO® today
At NIOX® we are passionate about providing excellent support and training.
